Novartis | NOVN - Assets


Novartis reported $122.03B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Alcon AG USD 31.1B 521M Jun/2026
Almirall EUR 2.37B 29.97M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Autolus Therapeutics Ltd USD 493.23M 33.84M Jun/2026
Bayer EUR 107.29B 659M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Fresenius EUR 41.84B 526M Jun/2026
Fresenius Medical Care EUR 31.29B 174.35M Jun/2026
Genmab DKK 12.52B 139M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
GRIFOLS EUR 20.09B 12M Jun/2026
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
J&J USD 201.06B 167M Jun/2026
Lakefront Biotherapeutics EUR 3.35B 21.24M Jun/2026
Lonza CHF 18.97B 164M Dec/2025
Merck EUR 52.69B 383M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Orion EUR 1.87B 205.5M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Philips EUR 26.7B 565M Jun/2026
Recordati EUR 5.37B 33.76M Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
UCB EUR 18.16B 971M Dec/2025